Aileen Chang
George Washington University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Aileen Chang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04597437 · Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)George Washington University · recruiting · Dengue Fever · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infectionU01AR079717 · NIAMS · GEORGE WASHINGTON UNIVERSITY · fiscal years 2022 to 2026 · $1,113,533 awarded in 2026Same name and institution; not confirmed by an ID
- The role of IL-2 therapy for Relapsing-Remitting Chikungunya ArthritisK23AR076505 · NIAMS · GEORGE WASHINGTON UNIVERSITY · fiscal years 2020 to 2022 · $155,174 awarded in 2022Same name and institution; not confirmed by an ID
- Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infectionR34AR075304 · NIAMS · GEORGE WASHINGTON UNIVERSITY · fiscal years 2020 · $351,997 awarded in 2020Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:37 UTC. The ranking covers the 200 most relevant of 477 PubMed records, and a shared surname and initials can bring in a namesake. All 477 on PubMed
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.N Engl J Med · 20181,131 citationsRCR 39.6
- Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness.Proc Natl Acad Sci U S A · 2015835 citationsRCR 37.1
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.Lancet Oncol · 2020419 citationsRCR 18.5
- 288 citationsRCR 13.0
- Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.J Clin Oncol · 2018276 citationsRCR 12.2
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.J Clin Oncol · 2021259 citationsRCR 13.2
- 249 citationsRCR 6.6
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.Lancet Oncol · 2021244 citationsRCR 14.3
- Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.N Engl J Med · 2020235 citationsRCR 12.1
- Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21.Clin Chem · 1999220 citationsRCR 6.4